文献速递乳腺癌支持与姑息治疗

心血管危险因素与乳腺癌患者心脏事件及生存结局的关联:SWOG临床试验分析

Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
PubMed 文献 · J Clin Oncol · 2018-03-27

该研究基于1999至2011年五项SWOG乳腺癌临床试验,通过链接Medicare索赔数据识别基线糖尿病、高血压、高胆固醇血症和冠心病,分析心血管危险因素(CVD-RFs)与总生存及心脏事件的关系。结果显示,每增加一个CVD-RF,死亡风险、心脏事件风险均增加;高胆固醇血症与改善的总生存相关。

要点

  • 每增加一个基线CVD-RF,死亡风险增加23%,心脏事件风险增加41%。
  • 87%的患者至少有一个CVD-RF,高血压和高胆固醇血症最常见。

核心结论

  • 每增加一个基线心血管危险因素与心脏事件风险和死亡风险增加相关。
  • 高胆固醇血症与改善的总生存相关,其他单个CVD-RF与总生存无关联。

研究设计与样本

  • 研究分析了1999至2011年五项SWOG乳腺癌临床试验中1460名66岁以上参与者。
  • 通过链接试验记录与Medicare索赔识别基线糖尿病、高血压、高胆固醇血症和冠心病。
  • 842名患者纳入生存分析,736名患者纳入心脏事件分析。

主要发现

  • 基线中位年龄70岁,中位随访6年;高血压占73%,高胆固醇血症占57%,87%患者有一个以上CVD-RF。

临床怎么用

  • 在乳腺癌临床试验参与者中,应关注基线CVD-RFs的评估和管理。
  • 尤其对具有多个CVD-RFs的患者,需加强可修饰CVD-RFs的控制。

局限性

  • 研究仅纳入66岁以上且链接Medicare索赔的临床试验参与者,可能限制普适性。
  • CVD-RFs通过索赔数据识别,可能存在 misclassification。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Cardiovascular disease is the primary cause of death among patients with breast cancer. However, the association of cardiovascular-disease risk factors (CVD-RFs) with long-term survival and cardiac events is not well studied. Methods We examined SWOG (formerly the Southwest Oncology Group) breast cancer trials from 1999 to 2011. We identified baseline diabetes, hypertension, hypercholesterolemia, and coronary artery disease by linking trial records to Medicare claims. The primary outcome was overall survival. Patients with both baseline and follow-up claims were examined for cardiac events. Cox regression was used to assess the association between CVD-RFs and outcomes. Results We identified 1,460 participants older than 66 years of age from five trials; 842 were eligible for survival outcomes analysis. At baseline, median age was 70 years, and median follow-up was 6 years. Hypertension (73%) and hypercholesterolemia (57%) were the most prevalent conditions; 87% of patients had one or more CVD-RF. There was no association between any of the individual CVD-RFs and overall survival except for hypercholesterolemia, which was associated with improved overall survival (hazard ratio [HR], 0.73; 95% CI, 0.57 to 0.93; P = .01). With each additional CVD-RF, there was an increased risk of death (HR, 1.23; 95% CI, 1.08 to 1.40; P = .002), worse progression-free survival (HR, 1.12; 95% CI, 1.00 to 1.25; P = .05), and marginally worse cancer-free survival (HR, 1.15; 95% CI, 0.99 to 1.34; P = .07). The relationship between baseline CVD-RFs and cardiac events was analyzed in 736 patients. A strong linear association between the number of CVD-RFs and cardiac event was observed (HR per CVD-RF, 1.41; 95% CI, 1.17 to 1.69; P < .001). Conclusion Among participants in clinical trials, each additional baseline CVD-RF was associated with an increased risk of cardiac events and death. Efforts to improve control of modifiable CVD-RFs are needed, especially among those with multiple risk factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hershman DL, Till C, Shen S, et al. Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. J Clin Oncol. 2018. PMID: 29584550. doi:10.1200/JCO.2017.77.4414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。